Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupUrologic OncologyDiseaseVon Hippel-Lindau DiseaseSubgroupRenal Cell CarcinomaICD10Q85.8MeSHCarcinoma, Renal CellKidney Neoplasmsvon Hippel-Lindau DiseaseSequenceChemotherapyChemo-substanceBelzutifanPazopanibChemo-substanceBelzutifanPazopanibChemo-substanceBelzutifanPazopanibChemo-substanceBelzutifanPazopanibNo. Substances1 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlArthalgiaDiarrheaDyspneaEdemaEmetogenicityEmetogenicity (ASCO)HeadacheHyperglycemiaHypertensionHyperthyroidismHypoalbuminemiaHypokalemiaIncrease AminotransferasesLeukopeniaMucositisMyalgiasProteinuriaThrombocytopenia below 50 000/µlUpper Respiratory Tract InfectionVisual Disturbances only studiesPublicationAuthorJonasch EDiseaseLokal fortgeschrittenes oder metastasiertes Nierenzellkarzinom, assoziiert mit von Hippel-Lindau-Erkrankung ECOG 0-2VHL Syndrom mit assoziiertem Nierenzellkarzinom, ECOG 0-1OriginMD Anderson Cancer Center, Houston, USAUniversity of Texas, M.D. Anderson Cancer Center, Houston, USA, MK-6482-004 trialProtocols in Revision 2 protocols foundProtocols under revision.Belzutifan 120, von Hippel-Lindau disease (PID1947 V1.0)Pazopanib 800, von Hippel-Lindau disease (PID1958 V1.0)
